Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 5/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MLYCD | O95822 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998975 | 0.84 | GRM5 (0.54) | GRM5MAPTHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL9123942 | 0.79 | HPGD (0.48) | MAPTHSP90AA1HSP90AB1ALDH1A1KMT2A | |
| SCHEMBL3612518 | 0.78 | KMT2A (0.50) | HSP90AA1HTTALDH1A1KMT2AMEN1 | |
| SCHEMBL15088738 | 0.74 | MAPT (0.46) | HCAR3MAPTHTTALDH1A1KMT2A | |
| SCHEMBL2253612 | 0.72 | MLYCD (0.46) | HCAR3MAPTALDH1A1KMT2AHPGD | |
| SCHEMBL12853918 | 0.72 | HTT (0.63) | HCAR3MAPTHTTALDH1A1KMT2A | |
| SCHEMBL13095774 | 0.72 | HTT (0.65) | MAPTHTTALDH1A1KMT2AMEN1 | |
| SCHEMBL16875731 | 0.72 | ALDH1A1 (0.52) | MAPTALDH1A1HPGD | |
| SCHEMBL1092282 | 0.71 | KCNJ1 (0.47) | HCAR3MAPTKMT2ALMNAHPGD | |
| Formaldoxime SCHEMBL9271919 | 0.71 | KMT2A (0.44) | HSP90AA1HTTALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| US-8053446-B2 | Cyanoguanidine compounds | LEO PHARMA A/S (DK) | 2011-11-08 | — | — | US | disclosed |
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | LEO PHARMA A/S (DK) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312275-A1 | Novel Cyanoguanidine Compounds | MKI67, CCNA1, COL1A1 | GRM5 4179/4885HCAR3 478/4885MAPT 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.